HGH Fragment 176-191 is only a 16-amino acid fragment of the C-terminal region of hGH (residues 176-191) – not the entire 191-amino acid molecule of the hormone. Full hGH has a multi-axial effect: it stimulates growth (via IGF-1), affects glucose metabolism (diabetogenic effect) and triggers lipolysis. The fragment retains only the lipolytic domain and lacks the regions responsible for growth effects. In preclinical models, this means lipolysis without stimulating IGF-1, without cell growth and without impairing glucose metabolism. This separation of functions is the essence of this fragment as a research tool.
HGH Fragment 176-191 5mg
HGH Fragment 176-191 5 mg of lyophilisate is a native, 16-amino acid lipolytic fragment of the C-terminal region of growth hormone (residues 176-191) from the Endogenic line. In preclinical models, it stimulates lipolysis and inhibits lipogenesis in adipose tissue without affecting IGF-1 or cell growth – which distinguishes it from full hGH. Research Use Only
HGH Fragment 176-191 5 mg - Lipolytic Growth Hormone Fragment, Research Reagent
- HGH Fragment 176-191 5 mg of lyophilisate is a native, 16-amino acid lipolytic fragment of the C-terminal region of growth hormone (residues 176-191) from the Endogenic line.
- In preclinical models, it stimulates lipolysis and inhibits lipogenesis in adipose tissue without affecting IGF-1 or cell growth - which distinguishes it from full hGH.
Product status information
Chemical reagent intended exclusively for laboratory tests (Research Use Only). It is not a medicinal product, dietary supplement or food. It is not intended for use on humans or animals. Sales only to registered research units and laboratories.
HGH Fragment 176-191 (hGH Frag 176-191) is a synthetic, 16-amino acid peptide corresponding to the C-terminal region of human growth hormone – precisely residues 176-191 of its 191-amino acid molecule. This is a “pure” fragment of the lipolytic domain of hGH, belonging to the lineage Endogenous — reagents mapping naturally occurring fragments and derivatives of human regulatory peptides.
The molecule is of interest to pharmacologists for one reason: it reproduces the lipolytic activity of growth hormone, and at the same time it is devoid of the sequences responsible for its growth effects and impact on the IGF-1 axis. Full hGH has a multi-axial effect – it stimulates cell growth (mainly through IGF-1), affects glucose metabolism (diabetogenic effect) and triggers the breakdown of fat in adipose tissue.
HGH Fragment 176-191 retains only this last component. This is what makes it a model research tool lipolysis separated from the growth axis — without the confounding effects of growth signaling and IGF-1. The C-terminal region of hGH was identified as the domain responsible for part of the lipolytic effect already in the work on the lipolytic domain of growth hormone conducted by the group of Frank Ng and colleagues.
This reagent is supplied as 5 mg lyophilisate in a vial, for reconstitution with bacteriostatic water in laboratory conditions. The freeze-dried form ensures stability of the peptide before dissolution and allows researchers to prepare working concentrations tailored to the experimental design. Purity verified by HPLC ≥98%, identity confirmed by mass spectrometry, COA available for each batch.
Regulatory status
HGH Fragment 176-191 has never been granted medicinal product status in the EU, USA or anywhere in the world. No EMA/FDA authorization and no EFSA authorization as a dietary supplement ingredient. Communicating the product as a “slimming peptide”, “fat burner for biohackers” or “safe alternative to growth hormone” is contrary to the Research Use Only framework.
Growth hormone fragments as tools for studying lipolysis
Human growth hormone (hGH) is a protein with 191 amino acids, whose biological profile is multiaxial – it combines growth effects (mediated mainly by IGF-1), influence on carbohydrate metabolism (including diabetogenic effects) and direct lipolytic activity in adipose tissue. Already in the 1970s and 1980s, it was shown that these activities are to some extent separable and assigned to different regions of the molecule.
The C-terminal region of hGH (approximately residues 176–191) was identified as the domain responsible for part of the lipolytic effect, independent of the IGF-1 axis. This discovery opened a research direction: is it possible to reproduce the lipolysis of growth hormone itself without its growth and metabolic effects? HGH Fragment 176-191 is just such a recreated, synthetic copy of the native C-terminal domain – a peptide consisting of 16 amino acid residues with an intramolecular disulfide bridge, reproducing the core lipolytic region of growth hormone in its unmodified form.
HGH Fragment 176-191 therefore belongs to the group peptide fragments of growth hormone — tools enabling the study of individual axes of hGH action in isolation. In category lipolytic peptides the closest relative here is AOD-9604, a tyrosine-defined and stabilized variant of the same lipolytic C-terminal domain; AOD-9604 is created by adding a tyrosine residue at the N-terminus of the fragment, which tidies up the molecule and facilitates detection without changing the basic lipolytic profile.
HGH Fragment 176-191 is the native form, without this modification. A full overview of the differences between both fragments is provided in the product datasheet AOD-9604. The biological profile of lipolytic growth hormone fragments observed in preclinical models includes:
- Lipolysis stimulation — stimulation of the breakdown of triglycerides in adipocytes, imitating the lipolytic C-terminal region of hGH
- Inhibition of lipogenesis — limiting the synthesis and deposition of new fat in adipose tissue
- No growth activity — unlike full hGH, the fragment does not significantly stimulate IGF-1 synthesis or cell growth
- Neutral glucose profile — no diabetogenic effect typical of full growth hormone in preclinical models
- Fat-loss specific profile — selective activity at the level of lipid metabolism without a multiaxial full hormone profile
HGH Fragment 176-191 occupies the position of the native lipolytic core in this group – the unmodified reference point against which stabilized derivative variants such as AOD-9604 are compared.
What is HGH Fragment 176-191?
Chemically, HGH Fragment 176-191 is a short peptide corresponding to the C-terminal fragment of growth hormone with an intramolecular disulfide bridge, without additional modifications.
- Common name: HGH Fragment 176-191, hGH Frag 176-191, growth hormone lipolytic fragment
- Chemical name: fragment hGH (176-191) – hGH(176-191) with a Cys-Cys bridge
- Synonyms: hGH 176-191, HGH Frag, lipolytic fragment of hGH, C-terminal fragment of growth hormone
- Sequence: Leu-Arg-Ile-Val-Gln-Cys-Arg-Ser-Val-Glu-Gly-Ser-Cys-Gly-Phe (with a disulfide bridge between Cys residues; residues 176-191 of hGH)
- CAS number: 66004-57-7 (in case of uncertainty – “to be verified in the batch COA”)
- Molar mass: ~1817 g/mol (to be verified in the batch COA)
- Chemical class: a synthetic 16-amino acid fragment of the C-terminal region of human growth hormone (region 176-191); lipolytic peptide without growth activity and IGF-1
- Delivered form: 5 mg lyophilisate in a vial, for reconstitution with bacteriostatic water; research grade ≥98% HPLC
Origin: HGH Fragment 176-191 comes directly from research on the lipolytic domain of growth hormone conducted, among others, by the group of Frank Ng and colleagues. The starting point was the observation that part of the lipolytic effect of hGH is caused by its C-terminal region, which can be reproduced in the form of a synthetic fragment.
Fragment 176-191 is the native, unmodified sequence of this region – a direct copy of the corresponding section of the 191-amino acid hGH molecule. Based on the same domain, the Australian Metabolic Pharmaceuticals team later developed its stabilized variant (AOD-9604, by adding tyrosine at the N-terminus), developed as an anti-obesity drug candidate. HGH Fragment 176-191 remains the native lipolytic core of this group – a research tool in the pharmacology of adipose tissue.
Mechanism of action at the molecular level
HGH Fragment 176-191 reproduces the lipolytic activity of the C-terminal region of growth hormone, while bypassing its growth activity. This separation of functions is the most important pharmacological feature of this fragment and the reason for its importance as a research tool. Pharmacological profile observed in preclinical models:
- Stimulation of lipolysis in adipocytes — in isolated fat cells and rodent models, the lipolytic fragment of hGH stimulated the breakdown of stored triglycerides into free fatty acids and glycerol, imitating the lipolytic action of the C-terminal domain of growth hormone. The mechanism was associated with stimulation of lipid metabolism at the level of adipose tissue and an increase in the oxidative activity of fatty acids (Ng et al., 2000; Heffernan et al., 2001)
- Inhibition of lipogenesis — in parallel to stimulating fat breakdown, the fragment limited the synthesis of new lipids (lipogenesis) in adipose tissue; this bidirectional profile – more breakdown, less synthesis – was the rationale for interest in the C-terminal domain of hGH as a direction for research on fat metabolism
- No effect on IGF-1, glucose and cell growth — this is the main distinction from full growth hormone. In preclinical models, the lipolytic fragment of hGH did not significantly stimulate the synthesis of IGF-1, did not have a diabetogenic effect (it did not worsen the glucose metabolism characteristic of excess hGH) and did not stimulate cell or tissue growth. The lipolytic C-terminal domain has been separated from the regions responsible for growth effects and insulin resistance – the fragment does not cause insulin resistance or growth effects typical of the hormone
- Possible involvement of β3-adrenergic signaling and mitochondrial metabolism — some studies indicate that the lipolytic effect of the C-terminal fragment may involve the β3-adrenergic receptor and modulation of lipid oxidation in adipocyte mitochondria; the mechanism at the molecular level remains under investigation and is not fully characterized
- Fat-loss specific profile — the entire observed phenotype is interpreted as selective lipolytic activity, separated from the multiaxial profile of full growth hormone; it is this selectivity that makes the fragment a model tool for studying adipose tissue metabolism
Pharmacokinetic profile (based on preclinical models and data for related fragments):
- Plasma half-life: short, ranging from minutes to hours – typical of short peptides sensitive to proteolysis
- Oral bioavailability: low – availability after administration through the gastrointestinal tract is limited by peptide degradation
- Metabolism: hydrolysis of peptide bonds by plasma and tissue peptidases
- Human PK profile for native fragment 176-191: only partially characterized; most clinical data relate to the stabilized AOD-9604 variant
In rodent models and isolated adipocytes, exposure to the lipolytic fragment of hGH led to an increase in the release of free fatty acids and an increase in their oxidation with no growth effects — phenotype interpreted as lipolysis separated from the IGF-1 axis.
IMPORTANT DISTINCTION
HGH Fragment 176-191 is a fragment of growth hormone, but it is not a growth hormone and it doesn’t recreate his profile. In preclinical models, the fragment retains the lipolytic activity of the C-terminal domain of hGH, but it does not stimulate the synthesis of IGF-1, does not cause growth effects or worsen glucose metabolism in a way typical of full growth hormone.
This is the first and most important distinction: HGH Frag vs full hGH – fragment does not raise IGF-1. The second distinction concerns the related AOD-9604: it is the same lipolytic core, but with added tyrosine at the N-terminus (Tyr-176-191), giving it greater stability and facilitating analytical detection; HGH Fragment 176-191 is the “pure” form, without tyrosine modification.
The terms “stimulation of lipolysis” and “inhibition of lipogenesis” refer only to observations in in vitro and in vivo models. This does not mean a guarantee of effect in humans or a suggestion of using the fragment as a “fat burner”, “reduction peptide” or “safe version of growth hormone”. The fragment remains a research tool.
HGH Fragment 176-191 and full hGH – pharmacological position: The value of a native snippet as a research tool comes from what’s in it There isn’t: :
- Full hGH (191 aa) — multiaxial profile: growth (IGF-1), glucose management (diabetogenic effect), lipolysis. Difficult to use as a tool to study lipolysis itself because all effects appear simultaneously
- HGH Fragment 176-191 — native lipolytic C-terminal fragment; the core of lipolytic activity without a growth axis, in an unmodified, “pure” form. Reference point for related variants
- AOD-9604 — defined, tyrosine-stabilized variant of the same lipolytic fragment; the same C-terminal domain with an additional Tyr residue at the N-terminus for stability and detection
Applications in scientific research
HGH Fragment 176-191 is used as a research reagent in several areas of metabolic pharmacology. In vitro models (isolated adipocytes, fat cell cultures) examine its effect on lipolysis, lipogenesis and fatty acid oxidation. In vivo models (rat, mouse, nutritional and genetic obesity models) assess parameters of fat metabolism, body composition and lipid markers – with no effect on the IGF-1 axis. Specific research directions include:
- Pharmacology of lipolysis independent of the growth axis — native fragment 176-191 as a model compound to study how the C-terminal domain of hGH mobilizes fat without stimulating IGF-1 and cell growth
- Models of obesity — assessment of the impact on adipose tissue metabolism, release and oxidation of free fatty acids and body composition in nutritional and genetic obesity models
- Separation of growth hormone activity — comparative studies of fragment vs. full hGH, aimed at understanding which regions of the molecule are responsible for particular axes of action
- Native fragment vs. stabilized variant comparisons — studies of differences in the profile of fragment 176-191 and its tyrosinated analogue AOD-9604, including the impact of N-terminal modification on stability and activity
- β3-adrenergic signaling and mitochondrial metabolism — study of the involvement of the β3 receptor and lipid oxidation in mitochondria in the lipolytic effect of the peptide
Summary
HGH Fragment 176-191 (hGH Frag 176-191) is a synthetic, 16-amino acid peptide corresponding to the native C-terminal region (residues 176-191) of human growth hormone, with an intramolecular disulfide bridge. Reproduces the lipolytic activity of hGH: in preclinical models it stimulates lipolysis and inhibits lipogenesis in adipose tissue, without stimulating IGF-1 synthesis, cell growth or worsening glucose metabolism — which is the most important distinction from full growth hormone (HGH Frag does not raise IGF-1).
Unlike the related AOD-9604, fragment 176-191 is the native form, without an added tyrosine at the N-terminus – AOD-9604 has this Tyr residue for greater stability. The probable lipolytic mechanism involves the β3-adrenergic receptor and mitochondrial metabolism. Lyophilized form 5 mg in a vial, reconstitution with bacteriostatic water, HPLC purity ≥98%, MS Q-TOF, COA for each batch.
Regulatory Status – Research Use Only; lack of registration as a medicine; WADA: section S2.2.3 (growth hormone fragments, named), prohibited at all times. The broader context of the selection and comparison of compounds with lipolytic activity – from peptides to thermogenics – is discussed in the review effective fat burners, and describes the framework for use in the cut phase protocol for reducing body fat.
Both materials are educational in nature and do not refer to the native fragment 176-191 as a product for use.
Bibliography
- Ng FM, Sun J, Sharma L, Libinaka R, Jiang WJ, Gianello R (2000). Metabolic studies of a synthetic lipolytic domain (AOD9604) of human growth hormone. PubMed
- Heffernan MA, Thorburn AW, Fam B, Summers R, Conway-Campbell B, Waters MJ, et al. (2001). Increase of fat oxidation and weight loss in obese mice caused by chronic treatment with human growth hormone or a modified C-terminal fragment. PubMed
- Wu Z, Ng F M (1993). Antilipogenic action of synthetic C-terminal sequence 177-191 of human growth hormone. PubMed
- Ng FM, Bornstein J (1978). Hyperglycemic action of synthetic C-terminal fragments of human growth hormone. PubMed
FAQ
Both peptides reproduce the same lipolytic C-terminal domain of growth hormone, but differ in structure. HGH Fragment 176-191 is the native form – an unmodified sequence of residues 176-191. AOD-9604 is the same core with added tyrosine residue at the N-terminus (Tyr-176-191), introduced for greater stability of the molecule and easier analytical detection. Tyrosine has a mainly structural and analytical function – it organizes the molecule without changing the basic lipolytic profile. AOD-9604 is therefore a defined, stabilized variant; HGH Fragment 176-191 is a “pure”, native reference fragment.
The biological activities of growth hormone are assigned to different regions of its molecule. The region responsible for stimulating IGF-1 synthesis and cell growth lies beyond the C-terminal lipolytic fragment. HGH Fragment 176-191 only reproduces the C-terminal domain (residues 176-191), so it does not contain sequences activating the IGF-1 axis. In preclinical models, this translates into no significant effect on IGF-1, no growth effects and a neutral glucose profile – unlike full hGH, which stimulates all these axes simultaneously. The fragment does not cause insulin resistance typical of excess hormone.
In isolated adipocytes and rodent models, the lipolytic fragment of hGH stimulated the breakdown of stored triglycerides into free fatty acids and glycerol and enhanced their oxidation, while inhibiting the synthesis of new lipids. This whole metabolic phenotype comes out without simultaneous stimulation of the IGF-1 axis and cell growth – hence the term “lipolysis separated from the growth axis”. The probable mechanism involves the participation of the β3-adrenergic receptor and modulation of lipid oxidation in mitochondria. The observations are from in vitro and in vivo models and do not constitute evidence of an effect in humans.
HGH Fragment 176-191 is a fragment of human growth hormone. Although it has no IGF-1 increasing activity or effects on IGF-1 in preclinical models, the 2026 WADA Prohibited List names it (as hGH 176-191) in section S2.2.3 (growth hormone, its analogues and fragments), so it is prohibited at all times, in and out of competition.
HGH Fragment 176-191 is a short peptide with a disulfide bridge, sensitive to thermal degradation, oxidation and mechanical stress. Reconstitution is carried out gently – a stream of solvent on the wall of the vial, without vigorous shaking, which generates foam and may damage the disulfide bridge.
It is best to use the working solution fresh or divide it into aliquots and freeze it, avoiding multiple freezing and thawing cycles.
-
Nicola
Product review
Fast delivery within Europe. I recommend.
-
Piotr
Polski
Product review
Najlepsze peptydy. Przetestowałem wszystkie laby z top 5 Google. Endogenic wymiata w każdym aspekcie.
-
Patryk P.
Polski Verified purchase
Product review
Zamawiałem wcześniej z innego labu oraz z Pro-Peptydy — jakość nieporównywalna. Zdecydowanie polecam!
-
Radek Ol.
Polski Verified purchase
Product review
Doskonały kontakt i pełen profesjonalizm! Otrzymałem szczegółowe wyjaśnienia dotyczące produktu. Ogromna wiedza, fachowe podejście i świetna obsługa. Zdecydowanie polecam firmę Endogenic oraz produkt, jakim jest Fragment.
-
Mary
Polski Verified purchase
Product review
Najlepszy ♥️
-
Sajmon
Polski
Product review
Polecam.
-
Marek
Polski
Product review
Fajny produkt.
-
Damian N
Polski
Product review
Najlepszy na rynku! Szybka dostawa i pomocna obsługa. 5*!